This content is machine translated Mantle cell lymphoma Recurrence after BTK inhibition – prognostic factors and treatment options Mantle cell lymphoma (MCL) is a rare B-cell non-Hodgkin’s lymphoma with a markedly heterogeneous course. The spectrum ranges from indolent, slowly progressive forms to highly aggressive variants. Diagnosis and treatment...…
View Post 5 min This content is machine translated ICML 2017 in Lugano Long-term data are positive At the ICML Congress, the audience gained insight into long-term data from two phase III trials in mantle cell lymphoma and chronic lymphocytic leukemia. The new results confirm the statements…
View Post 4 min This content is machine translated Mantle cell lymphoma First- and second-line lenalidomide Mantle cell lymphoma (MZL) is an aggressive non-Hodgkin’s lymphoma that accounts for approximately 3-6% of all NHL cases. It has a poor prognosis, especially after failure of first-line therapy. Lenalidomide…
